Premium
Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases
Author(s) -
Kasagi K.,
Takeuchi R.,
Miyamoto S.,
Misaki T.,
Inoue D.,
Shimazu A.,
Mori T.,
Konishi J.
Publication year - 1994
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1994.tb03942.x
Subject(s) - medicine , thyroid , endocrinology , antibody , thyroid carcinoma , follicular phase , thyroid cancer , cancer , immunology
Summary Three patients with metastatic thyroid follicular carcinoma developed thyrotoxicosis. Two had mild T3 toxicosis without detectable TSH binding inhibitor immunoglobulins (TBII) or thyroid stimulating antibodies (TSAb). Considerable concentration of 131 ***I by tumours occurred, although serum TSH was undetectable. The third patient developed thyrotoxicosis several months after treatment with 131 I had commenced and this was associated with concurrent increase in both TBII (90%; normal, less than 11%) and TSAb (2100%). We conclude that thyrotoxicosis in patients with metastatic thyroid carcinoma may result from a large bulk of tumour functioning either autonomously or after stimulation by TSH receptor antibodies.